ATLASATLAS fair value
ATLAS has no fair value for this stock today.
TScan Therapeutics (TCRX)
TScan Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.19▲ +1.05%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
43%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on TScan Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On TScan Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives TScan Therapeutics a 43% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $0.15 and $0.22; in 9 out of 10, between $0.10 and $0.32. Estimated annual volatility is 125%.
Price, last 12 months (weekly close)
Key numbers
- 52-week high
- $2.28
- 52-week low
- $0.18
- Revenue (12 months)
- $7.1M
- Revenue growth (YoY)
- +266.7%
- Gross margin
- 0.0%
- Return on equity
- -95.8%
- Free cash flow (12 months)
- $-79.9M
- Beta
- 1.07
What this means
ATLAS does not publish a fair value for TCRX right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks TCRX has traded between $0.18 and $2.28. Today it is 91.6% below that high and 6% above its low.
Its beta is 1.07: it moves roughly in line with the market.
About the company
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer.
Want to see everything about TScan Therapeutics?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does TScan Therapeutics do?
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer.
What is the chance TCRX goes up next month?
43%: somewhat worse than a coin flip. In half of the simulated outcomes, TCRX ends the month between $0.15 and $0.22.
How volatile is TCRX?
ATLAS estimates annual volatility at 125%. In a typical month, half of the outcomes end between $0.15 and $0.22.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer